Avaleht › Ülekaalulisus › Tennessee
Ülekaalulisus kliinilised uuringud osariigis Tennessee
25 uuringut haiguse Ülekaalulisus jaoks otsivad osalejaid osariigis Tennessee.
Linnad osariigis Tennessee
Ametlik uuringutekst (inglise keeles)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Holston Medical Group - Bristol /ID# 282045, Bristol
- New Phase Research & Development /ID# 282131, Knoxville
- Summit Medical Group- Halls Family Physicians /ID# 282435, Knoxville
- ja veel 1
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 2. okt 2026 · NCT07752979AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- M3 Wake Research Chattanooga, Chattanooga
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 30. sept 2026 · NCT07533175A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- LifeDoc Health, Memphis
VärbamineFaas 3
Vanused 8–18 · Kõik sood · Uuendatud 30. sept 2026 · NCT07253285Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- AMR Clinical, Nashville
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 28. sept 2026 · NCT07837973A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- New Phase Research and Development, Knoxville
- Clinical Research Associates Inc, Nashville
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 28. sept 2026 · NCT07794579Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastroenterology Center Of The Midsouth, Cordova
VärbamineFaas 3
Vanused 18–70 · Kõik sood · Uuendatud 24. sept 2026 · NCT06937099A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Vanderbilt Health One Hundred Oaks, Nashville
VärbamineFaas 3
Vanused 6–17 · Kõik sood · Uuendatud 24. sept 2026 · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastroenterology Center Of The Midsouth, Cordova
VärbamineFaas 3
Vanused 18–70 · Kõik sood · Uuendatud 24. sept 2026 · NCT06937086A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Franklin
- Research Site, Jackson
- Research Site, Knoxville
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Stern Cardiovascular Foundation Inc, Germantown
- Accellacare of Knoxville, Knoxville
- Cardiovascular Research of Knoxville North Knoxville Medical Center, Powell
- ja veel 1
VärbamineFaas 3
Vanused 45–99 · Kõik sood · Uuendatud 22. sept 2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- AMR Clinical, Nashville
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT07321886A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Quality Medical Research, Nashville
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 22. sept 2026 · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Memphis
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 16. sept 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Memphis
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 16. sept 2026 · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Innovative Clinical Research, Clarksville
- Clinical Research Associates, Nashville
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 14. sept 2026 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Nashville
VärbamineFaas 3Terved vabatahtlikud oodatud
Vanused 18–79 · Kõik sood · Uuendatud 11. sept 2026 · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Quality Medical Research, Nashville
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 8. sept 2026 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- DelRicht Research - Thompson's Station, Smyrna
VärbamineFaas 4
Vanused 18 ja vanemad · Kõik sood · Uuendatud 4. sept 2026 · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailea Clinical Site, Memphis
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 3. sept 2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- New Phase Research and Development, Knoxville
VärbamineFaas 3
Vanused 18–99 · Kõik sood · Uuendatud 3. sept 2026 · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Chattanooga
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 3. sept 2026 · NCT07284875A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Kingsport
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. aug 2026 · NCT07784725Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Knoxville
VärbamineFaas 3
Vanused 18–79 · Kõik sood · Uuendatud 10. aug 2026 · NCT07654361Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
- Holston Medical Group_Bristol, Bristol
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. juuni 2026 · NCT07607587A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
- MBX Biosciences Investigational Site, Knoxville
VärbamineFaas 1
Vanused 18–65 · Kõik sood · Uuendatud 9. juuni 2026 · NCT07142707Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.